Due to the success story of the product and the established commitment, it is hoped that Cuban therapy can reduce the relative risk of amputation due to diabetic foot ulcer in the United States.
The Cuban company Heber Biotec and the American company Mercurio Biotec have agreed to join efforts to bring Heberprot-P therapy to patients with diabetic foot ulcer (UPD) in the USA. US, once approved by the Drug and Food Administration of that nation (the FDA, for its acronym in English).
Due to the success story of the product and the commitment established between Mercury and Heber, it is hoped that Cuban therapy can reduce the relative risk of amputation by UPD in the United States. In more than half of the current figures, as reported in a press release by the business group BioCubaFarma.
Nearly one million American patients debut with UPD annually. This complication increases the risk of amputations of the lower extremities. In five years, the number of amputees in the US UU it has increased from 73,000 to 85,000, with negative consequences for families and health systems, social and economic effects.